Debbie Rigby takes a look at the latest in research news
Studies have shown SARS‐CoV‐2, a novel virus that causes COVID‐19 infection, causes worse outcomes and a higher mortality rate in older adults and those with comorbidities such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease.
Journal of the American Geriatrics Society 2020.
This report concludes that in patients with cardiovascular disease and SARS-CoV2, the use of ACE inhibitors, ARBs [angiotensin receptor blockers], or MRAs [mineralocorticoid-receptor antagonists] may be favorable as a method to endogenously upregulate ACE2 as a compensatory mechanism that provides anti-inflammatory, antifibrotic, and antithrombotic support as well as reduction in progression of vascular/cardiac remodeling and heart failure.
Journal of the American College of Cardiology, available online 16 April 2020.
Data from the China epidemic and the COVID-19 deaths show that most of those patients were old and commonly affected by CVD. This article discusses the role of ACE2 in the CV system and in acute respiratory syndromes. There is no evidence that these drugs can improve or worsen SARS-CoV-2 lung invasion and COVID-19 course.
European Journal of Preventive Cardiology, first published April 15, 2020.
This editorial comments on three studies published in the same edition and concludes that patients should not discontinue ACE inhibitor or ARB therapy out of a concern that they are at increased risk for infection, severe illness, or death during the Covid-19 pandemic. Each of these studies has weaknesses inherent in observational data, but it is reassuring that they deliver a consistent message that the continued use of ACE inhibitors and ARBs is unlikely to be harmful in patients with COVID-19.
New Engl J Med 2020.